vs
Armour Residential REIT, Inc.（ARR）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
RIGEL PHARMACEUTICALS INC的季度营收约是Armour Residential REIT, Inc.的1.4倍（$69.8M vs $50.4M），Armour Residential REIT, Inc.净利率更高（420.2% vs 384.0%，领先36.2%），Armour Residential REIT, Inc.同比增速更快（297.9% vs 21.2%），过去两年Armour Residential REIT, Inc.的营收复合增速更高（108.0% vs 53.7%）
Armour Residential REIT, Inc.是一家总部位于美国的房地产投资信托企业，主要投资由美国政府支持机构担保的机构级住宅抵押贷款支持证券，通过专业资产管理和风险管控为股东创造长期稳定的净收益。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
ARR vs RIGL — 直观对比
营收规模更大
RIGL
是对方的1.4倍
$50.4M
营收增速更快
ARR
高出276.7%
21.2%
净利率更高
ARR
高出36.2%
384.0%
两年增速更快
ARR
近两年复合增速
53.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $50.4M | $69.8M |
| 净利润 | $211.7M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | — | 33.2% |
| 净利率 | 420.2% | 384.0% |
| 营收同比 | 297.9% | 21.2% |
| 净利润同比 | 555.9% | 1769.2% |
| 每股收益（稀释后） | $2.43 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARRRIGL
| Q4 25 | $50.4M | $69.8M | ||
| Q3 25 | $38.5M | $69.5M | ||
| Q2 25 | $33.1M | $101.7M | ||
| Q1 25 | $36.3M | $53.3M | ||
| Q4 24 | $12.7M | $57.6M | ||
| Q3 24 | — | $55.3M | ||
| Q2 24 | $7.0M | $36.8M | ||
| Q1 24 | — | $29.5M |
净利润ARRRIGL
| Q4 25 | $211.7M | $268.1M | ||
| Q3 25 | $159.3M | $27.9M | ||
| Q2 25 | $-75.6M | $59.6M | ||
| Q1 25 | $27.3M | $11.4M | ||
| Q4 24 | $-46.4M | $14.3M | ||
| Q3 24 | — | $12.4M | ||
| Q2 24 | $-48.4M | $-1.0M | ||
| Q1 24 | — | $-8.2M |
毛利率ARRRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率ARRRIGL
| Q4 25 | — | 33.2% | ||
| Q3 25 | — | 40.9% | ||
| Q2 25 | — | 60.1% | ||
| Q1 25 | — | 23.9% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 25.4% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | -23.6% |
净利率ARRRIGL
| Q4 25 | 420.2% | 384.0% | ||
| Q3 25 | 413.5% | 40.2% | ||
| Q2 25 | -228.4% | 58.6% | ||
| Q1 25 | 75.2% | 21.5% | ||
| Q4 24 | -366.8% | 24.9% | ||
| Q3 24 | — | 22.5% | ||
| Q2 24 | -693.8% | -2.8% | ||
| Q1 24 | — | -27.9% |
每股收益（稀释后）ARRRIGL
| Q4 25 | $2.43 | $14.11 | ||
| Q3 25 | $1.49 | $1.46 | ||
| Q2 25 | $-0.94 | $3.28 | ||
| Q1 25 | $0.32 | $0.63 | ||
| Q4 24 | $-0.91 | $0.82 | ||
| Q3 24 | — | $0.70 | ||
| Q2 24 | $-1.05 | $-0.06 | ||
| Q1 24 | — | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.3M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $2.3B | $391.5M |
| 总资产 | $21.0B | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ARRRIGL
| Q4 25 | $63.3M | $155.0M | ||
| Q3 25 | $44.2M | $137.1M | ||
| Q2 25 | $141.2M | $108.4M | ||
| Q1 25 | $49.1M | $77.1M | ||
| Q4 24 | $68.0M | $77.3M | ||
| Q3 24 | — | $61.1M | ||
| Q2 24 | $126.6M | $49.1M | ||
| Q1 24 | — | $49.5M |
总债务ARRRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益ARRRIGL
| Q4 25 | $2.3B | $391.5M | ||
| Q3 25 | $2.1B | $117.6M | ||
| Q2 25 | $1.7B | $81.9M | ||
| Q1 25 | $1.7B | $18.6M | ||
| Q4 24 | $1.4B | $3.3M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | $1.2B | $-29.9M | ||
| Q1 24 | — | $-31.7M |
总资产ARRRIGL
| Q4 25 | $21.0B | $513.6M | ||
| Q3 25 | $19.4B | $242.5M | ||
| Q2 25 | $16.2B | $206.7M | ||
| Q1 25 | $15.5B | $176.0M | ||
| Q4 24 | $13.5B | $164.0M | ||
| Q3 24 | — | $139.4M | ||
| Q2 24 | $10.1B | $128.4M | ||
| Q1 24 | — | $126.5M |
负债/权益比ARRRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $124.2M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 0.59× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ARRRIGL
| Q4 25 | $124.2M | $22.0M | ||
| Q3 25 | $-37.8M | $24.0M | ||
| Q2 25 | $25.0M | $30.5M | ||
| Q1 25 | $101.5M | $-893.0K | ||
| Q4 24 | $261.5M | $14.5M | ||
| Q3 24 | — | $21.7M | ||
| Q2 24 | $27.1M | $302.0K | ||
| Q1 24 | — | $-5.0M |
现金转化率ARRRIGL
| Q4 25 | 0.59× | 0.08× | ||
| Q3 25 | -0.24× | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | 3.71× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
